Total Payments
$652,988
2024 Payments
$70,067
Companies
49
Transactions
2,287
Medicare Patients
25,525
Medicare Billing
$9.3M
Payment Breakdown by Category
Other$435,857 (66.7%)
Research$98,540 (15.1%)
Travel$55,150 (8.4%)
Food & Beverage$40,180 (6.2%)
Consulting$22,742 (3.5%)
Education$518.19 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $333,845 | 137 | 51.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $102,012 | 62 | 15.6% |
| Unspecified | $98,540 | 9 | 15.1% |
| Travel and Lodging | $55,150 | 175 | 8.4% |
| Food and Beverage | $40,180 | 1,885 | 6.2% |
| Consulting Fee | $22,742 | 11 | 3.5% |
| Education | $518.19 | 8 | 0.1% |
Payments by Type
General
$554,447
2,278 transactions
Research
$98,540
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $258,381 | 417 | $0 (2023) |
| Horizon Pharma plc | $126,578 | 183 | $0 (2018) |
| Eli Lilly and Company | $97,319 | 6 | $0 (2024) |
| Lilly USA, LLC | $54,494 | 207 | $0 (2024) |
| Amgen Inc. | $50,256 | 287 | $0 (2024) |
| GENZYME CORPORATION | $29,404 | 67 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $6,863 | 42 | $0 (2019) |
| ABBVIE INC. | $5,983 | 285 | $0 (2024) |
| UCB, Inc. | $3,995 | 70 | $0 (2024) |
| Janssen Biotech, Inc. | $3,835 | 140 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $70,067 | 243 | Amgen Inc. ($46,902) |
| 2023 | $115,233 | 277 | Horizon Therapeutics plc ($96,329) |
| 2022 | $44,854 | 215 | Horizon Therapeutics plc ($28,912) |
| 2021 | $36,095 | 235 | Horizon Therapeutics plc ($20,822) |
| 2020 | $35,387 | 212 | Horizon Therapeutics plc ($25,064) |
| 2019 | $203,671 | 386 | Eli Lilly and Company ($89,679) |
| 2018 | $79,670 | 351 | Horizon Pharma plc ($68,554) |
| 2017 | $68,012 | 368 | Horizon Pharma plc ($58,024) |
All Payment Transactions
2,287 individual payment records from CMS Open Payments — Page 1 of 92
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/19/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/17/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/12/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,700.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Consulting Fee | Cash or cash equivalent | $2,465.00 | General |
| Category: Rheumatology | ||||||
| 12/12/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $450.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/11/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $10.98 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $28.03 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | Fresenius Kabi USA, LLC | Tyenne (Biological) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: Biosimilars | ||||||
| 12/04/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: Bone Health | ||||||
| 12/04/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $13.43 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/26/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.09 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: Bone Health | ||||||
| 11/20/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $26.89 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/18/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $26.33 | General |
| Category: Immunology | ||||||
| 11/13/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/12/2024 | Organon Llc | HADLIMA (Drug) | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: ADALIMUMAB-BWWD | ||||||
| 11/11/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Travel and Lodging | In-kind items and services | $1,402.50 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/11/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: Analgesic | ||||||
| 11/07/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/07/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 11/06/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Inflammation/Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | Eli Lilly and Company | $90,029 | 2 |
| A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $6,178 | 2 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) | CSL Behring | $1,222 | 3 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, TWO-ARM, PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $1,007 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | Eli Lilly and Company | $104.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 64 | 6,713 | 263,217 | $6.9M | $2.7M |
| 2022 | 64 | 6,564 | 226,511 | $5.9M | $2.3M |
| 2021 | 68 | 6,491 | 231,743 | $5.5M | $2.3M |
| 2020 | 63 | 5,757 | 203,202 | $4.6M | $2.0M |
Total Patients
25,525
Total Services
924,673
Medicare Billing
$9.3M
Procedure Codes
259
All Medicare Procedures & Services
259 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 345 | 31,440 | $1.3M | $577,253 | 43.7% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 25 | 90,151 | $628,257 | $421,133 | 67.0% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 32 | 11,900 | $868,700 | $401,369 | 46.2% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 48 | 32,974 | $1.6M | $346,283 | 21.0% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 50 | 44,310 | $443,100 | $345,100 | 77.9% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 16 | 36,400 | $436,800 | $142,753 | 32.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 544 | 1,144 | $233,376 | $102,731 | 44.0% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 11 | 3,160 | $407,640 | $82,817 | 20.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 137 | 687 | $233,580 | $66,833 | 28.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 392 | 909 | $108,052 | $47,011 | 43.5% |
| 82306 | Vitamin d-3 level | Office | 2023 | 381 | 543 | $124,890 | $15,724 | 12.6% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 62 | 238 | $43,380 | $15,263 | 35.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 560 | 1,205 | $26,510 | $12,440 | 46.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 102 | 102 | $33,456 | $11,824 | 35.3% |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | Office | 2023 | 19 | 115 | $26,795 | $11,544 | 43.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 578 | 1,297 | $15,564 | $10,895 | 70.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 59 | 73 | $21,170 | $9,993 | 47.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 113 | 148 | $21,460 | $9,056 | 42.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 506 | 1,096 | $38,360 | $8,317 | 21.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $17,759 | $5,983 | 33.7% |
| 77085 | Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | Office | 2023 | 104 | 104 | $11,648 | $5,277 | 45.3% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 448 | 1,015 | $18,270 | $5,140 | 28.1% |
| 86480 | Tuberculosis test, gamma interferon | Office | 2023 | 79 | 80 | $12,800 | $4,822 | 37.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 31 | 184 | $22,080 | $3,982 | 18.0% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 161 | 173 | $9,515 | $2,848 | 29.9% |
About Dr. Mona Amin, D.O
Dr. Mona Amin, D.O is a Rheumatology healthcare provider based in Glendale, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1740476217.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mona Amin, D.O has received a total of $652,988 in payments from pharmaceutical and medical device companies, with $70,067 received in 2024. These payments were reported across 2,287 transactions from 49 companies. The most common payment nature is "Honoraria" ($333,845).
As a Medicare-enrolled provider, Amin has provided services to 25,525 Medicare beneficiaries, totaling 924,673 services with total Medicare billing of $9.3M. Data is available for 4 years (2020–2023), covering 259 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology
- Location Glendale, AZ
- Active Since 09/19/2007
- Last Updated 08/18/2022
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1740476217
Products in Payments
- KRYSTEXXA (Biological) $278,636
- RAYOS (Drug) $108,820
- TALTZ (Drug) $44,515
- KRYSTEXXA (Drug) $39,159
- KEVZARA (Biological) $23,735
- ACTHAR (Biological) $6,969
- OLUMIANT (Drug) $6,525
- NO PRODUCT DISCUSSED (Drug) $5,092
- LUPKYNIS (Drug) $3,135
- RINVOQ (Biological) $2,949
- TREMFYA (Drug) $2,808
- Enbrel (Biological) $2,323
- XELJANZ (Drug) $2,292
- PURIFIED CORTROPHIN GEL (Drug) $2,225
- Cimzia (Drug) $1,434
- Hizentra (Biological) $1,222
- COSENTYX (Biological) $1,084
- Humira (Biological) $974.99
- Rituxan (Biological) $970.01
- BENLYSTA (Biological) $825.15
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Glendale
Dr. Kurt Oelke, M.d, M.D
Rheumatology — Payments: $874,374
Rheumatology $874,374
Dr. John Albert, Md, MD
Rheumatology — Payments: $327,981
Rheumatology $327,981
Dr. Andrew Sharobeem, D.o, D.O
Rheumatology — Payments: $217,638
Rheumatology $217,638
Rajat Dhar, Md, MD
Rheumatology — Payments: $146,079
Rheumatology $146,079
Eric Peters, Md, MD
Rheumatology — Payments: $57,479
Rheumatology $57,479
Noune Pashinian, Md, MD
Rheumatology — Payments: $50,017
Rheumatology $50,017